Skip to main content

Table 3 Surgical outcomes

From: Comparison of efficacy and safety of neoadjuvant immunochemotherapy in young and elderly patients with IIA–IIIB non-small-cell lung cancer in real-world practice

Variables

Unmatched cases

Matched cases

< 65Y, n = 45

≥ 65Y, n = 64

P-value

< 65Y, n = 41

≥ 65Y, n = 36

P-value

Time from first treatment to surgery, median (IQR), day

80.7 (53.0-101.0)

80.9 (51.0-100.8)

0.638

72.0 (52.5-101.5)

60.0 (51.3–99.3)

0.675

Surgical approach, n (%)

  

0.953

  

0.603

Open

26 (57.8)

35 (54.7)

 

25 (61.0)

18 (50.0)

 

VATS

12 (26.7)

16 (25.0)

 

10 (24.4)

8 (22.2)

 

RATS

1 (2.2)

2 (3.1)

 

1 (2.4)

2 (5.6)

 

VATS-Open

6 (13.3)

11 (17.2)

 

5 (12.2)

8 (22.2)

 

Surgical method, n (%)

  

0.624

  

0.841

Wedge resection

1 (2.2)

3 (4.7)

 

1 (2.4)

1 (2.8)

 

Lobectomy

24 (53.3)

33 (51.6)

 

21 (51.2)

17 (47.2)

 

Sleeve resection

14 (31.1)

21 (32.8)

 

13 (31.7)

14 (38.9)

 

Total pneumonectomy

4 (8.9)

7 (10.9)

 

4 (9.8)

4 (11.1)

 

Segmental resection

2 (4.4)

0 (0.0)

 

2 (4.9)

0 (0.0)

 

Operation time, median (IQR), min

139.0 (107.0-175.0)

147.0 (106.0-196.0)

0.418

144.0 (109.0-175.0)

156.5 (124.8-216.8)

0.073

Estimated blood loss, median (IQR), mL

50.0 (20.0-57.5)

50.0 (20.0–60.0)

0.645

50.0 (35.0–90.0)

50.0 (20.0-57.5)

0.524

Resection margin, n (%)

  

1.000

  

1.000

R0

42 (93.3)

60 (93.8)

 

39 (95.1)

34 (94.4)

 

R1

3 (6.7)

4 (6,3)

 

2 (4.9)

2 (5.6)

 

Number of lymph node dissections during surgery, median (IQR), n

14.0 (10.0–21.0)

17.0 (11.0–25.0)

0.221

14.0 (10.0–23.0)

18.0 (12.3–25.8)

0.104

Length of hospital stay, median (IQR), day

9.5 (7.0–14.0)

14.0 (9.0–17.0)

0.009

10.0 (7.0–14.0)

14.0 (9.0–18.0)

0.029

Postoperative complication, n (%)

      

Overall

14 (31.1)

32 (50.0)

0.049

14 (34.1)

18 (50.0)

0.159

Hydropneumothorax

3 (6.7)

6 (9.4)

0.879

3 (7.3)

3 (8.3)

1.000

Hydrothorax

8 (17.8)

20 (31.3)

0.113

8 (19.5)

11 (30.6)

0.262

Pneumothorax

4 (8.9)

4 (6.3)

0.883

4 (9.8)

3 (8.3)

1.000

Chylothorax

0 (0.0)

1 (1.6)

1.000

0 (0.0)

1 (2.8)

0.948

Bronchial obstruction

0 (0.0)

1 (1.6)

1.000

0 (0.0)

1 (2.8)

0.948

Postoperative bleeding

0 (0.0)

1 (1.6)

1.000

0 (0.0)

1 (2.8)

0.948

Pathological grade, n (%)

  

0.268

  

0.152

G1

0 (0.0)

1 (1.6)

 

0 (0.0)

1 (2.8)

 

G2

6 (13.3)

16 (25.0)

 

6 (14.6)

11 (30.6)

 

G3

17 (37.8)

25 (39.1)

 

15 (36.6)

13 (36.1)

 

Unknown

22 (48.9)

22 (34.4)

 

20 (48.8)

11 (30.6)

 

ypTNM stage, n (%)

  

0.277

  

0.137

0

20 (44.4)

17 (26.6)

 

19 (46.3)

8 (22.2)

 

IA

9 (20.0)

16 (25.0)

 

8 (19.5)

7 (19.4)

 

IB

2 (4.4)

4 (6.3)

 

2 (4.9)

2 (5.6)

 

IIA

1 (2.2)

2 (3.1)

 

1 (2.4)

2 (5.6)

 

IIB

6 (13.3)

18 (28.1)

 

5 (12.2)

12 (33.3)

 

IIIA

7 (15.6)

6 (9.4)

 

6 (14.6)

4 (11.1)

 

IIIB

0 (0.0)

1 (1.6)

 

0 (0.0)

1 (2.8)

 
  1. Abbreviations: VATS, video-assisted thoracoscopic surgery; RATS, robot-assisted thoracoscopic surgery; IQR, interquartile range; ypTNM, post-neoadjuvant pathologic tumor-node-metastasis